CREUTZFELDT-JAKOB DISEASE SURVEILLANCE IN RECIPIENTS OF HUMAN GROWTH HORMONE

NIDDK Creutzfeldt-Jakob病监测在人类生长激素接受者项目由人类生长激素（hGH）和Creutzveldt-Jakob病（CJD）机构间委员会监督，包括NIDDK，NICHD，NINDS，CDC和FDA的代表。在1963年至1985年期间，国家激素计划（NHPP）将人类生长激素（hGH）发送给美国各地的数百名医生，治疗了大约7，700名生长失败的儿童。1985年，公共卫生服务部门注意到，在接受hGH作为NHPP一部分的个人中，有三人死于CJD，这是一种罕见且无法治愈的脑部疾病。NHPP立即停止分发hGH，并开始研究hGH和CJD之间的关系。目前，hGH和CJD机构间委员会跟踪已知已接受hGH作为NHPP一部分的个人队列。到目前为止，在美国的hGH接受者中已经有32例确诊的CJD病例。Westat是一个提供研究服务的组织，是协助hGH和CJD机构间委员会对hGH接受者进行随访的承包商。

The NIDDK Creutzfeldt-Jakob Disease Surveillance in Recipients of Human Growth Hormone project is overseen by the Interagency Committee on Human Growth Hormone (hGH) and Creutzveldt-Jakob Disease (CJD) and includes representives from NIDDK, NICHD, NINDS, CDC and FDA. Between 1963 and 1985, the National Hormone Pituitary Program (NHPP) sent human growth hormone (hGH) to hundreds of physicians across the United States, resulting in the treatment of approximately 7,700 children with growth failure. In 1985, it came to the attention of the Public Health Service that there had been three deaths due to CJD, a rare and incurable brain disease, in individuals who had received hGH as part of the NHPP. The NHPP immediately stopped distributing hGH and began a study to understand the relationship between hGH and CJD. Currently, the Interagency Committee on hGH and CJD follows the cohort of individuals who are known to have received hGH as part of the NHPP. To date, there have been 32 confirmed cases of CJD among hGH recipients in the U.S. Westat, an organization that provides research services, is the contractor that assists the Interagency Committee on hGH and CJD in the follow-up of hGH recipients.